{"id":"W2945268366","doi":"10.1093/annonc/mdz100.045","title":"Phase III study of [fam-] trastuzumab deruxtecan (DS-8201a) vs T-DM1 for HER2-positive breast cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Pertuzumab; Metastatic breast cancer; Oncology; Clinical endpoint; Breast cancer; Taxane; Population; Antibody-drug conjugate; Phases of clinical research; Cancer; Clinical trial; Immunology; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001146805,0.001345389,0.001918014,0.0004123431,0.0004177243,0.001316496,0.001161087,0.001316978,0.004613499],"category_scores_gemma":[0.0008126368,0.0006664456,0.001193725,0.0004233423,0.001002889,0.0009218604,0.0003109254,0.003289389,0.001390345],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001457074,"about_ca_system_score_gemma":0.001783389,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002859253,"about_ca_topic_score_gemma":0.006085878,"domain_scores_codex":[0.9996845,0.0001383175,0.00001186099,0.00006010322,0.00002128367,0.00008393479],"domain_scores_gemma":[0.9994349,0.0001071918,0.00008647918,0.00005255011,0.000026558,0.0002922335],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8017761,0.05646024,0.003615913,0.0005418167,0.001589758,0.0002305421,0.0002586025,0.004980416,0.03984484,0.0006515512,0.004531802,0.08551843],"study_design_scores_gemma":[0.6277555,0.3514642,0.007980622,0.00004316344,0.0006819718,0.0002728544,0.0001004797,0.002408547,0.004835811,0.0003956356,0.004022174,0.00003901764],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909161,0.002370222,0.0004916955,0.0007428716,0.0002509556,0.001085157,0.001332921,0.0001187941,0.002691376],"genre_scores_gemma":[0.9868989,0.00248811,0.001209875,0.0009029975,0.0002011197,0.00114934,0.002251906,0.00006379394,0.004833846],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004613499,"threshold_uncertainty_score":0.01543367,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1289387887831025,"score_gpt":0.5177291619702629,"score_spread":0.3887903731871604,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}